DDInter1161 DDInter1082
Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potential for addiction and abuse. The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Metamfetamine {u} (Compound) resembles {v} (Compound) Benzphetamine
Metamfetamine {u} (Compound) resembles {v} (Compound) Phenacemide
Metamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ephedrine
Metamfetamine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Metamfetamine {u} (Compound) treats {v} (Disease) obesity
Metamfetamine {u} (Compound) binds {v} (Gene) ADRA2C
Metamfetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Metamfetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Metamfetamine {u} (Compound) causes {v} (Side Effect) Tourette's disorder
Metamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Metamfetamine (Compound) resembles Benzphetamine (Compound)
Metamfetamine (Compound) resembles Phenacemide (Compound)
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Metamfetamine (Compound) treats obesity (Disease)
Metamfetamine (Compound) binds ADRA2C (Gene)
Metamfetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Metamfetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Metamfetamine (Compound) causes Tourette's disorder (Side Effect)
Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate